|
| VIEW POINT |
|
| Year : 2010 | Volume
: 56
| Issue : 3 | Page : 226-228 |
Clinically effective CK-MB reporting: How to do it?
S Vivekanandan1, R Swaminathan2
1 Department of Clinical Biochemistry, Global Hospitals & Health City, Chennai, India
2 Department of Chemical Pathology, Guy's & St. Thomas Hospitals NHS Trust, London SE1 7EH, United Kingdom
Correspondence Address:
S Vivekanandan
Department of Clinical Biochemistry, Global Hospitals & Health City, Chennai
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0022-3859.68646
The clinical utility of measuring the Muscle Brain (MB) isoenzyme of creatine kinase (CK) in the diagnosis of myocardial injury is well established. CK/CK-MB measurement in combination or CK-MB alone is widely used and reporting the results of CK-MB in absolute unit is the common current practice. CK-MB is widely measured by "Immunoinhibition" in India, which gives falsely elevated CK-MB results in the following circumstances: Central nervous system damage, childbirth, macro CK-immunoglobulin complex, in patients with carcinoma of various organs, such as prostate carcinoma and other adenocarcinomas. But, reporting %CK-MB rather than the absolute CK-MB results assists in detection of macroCK (or CK variants), associated proliferative and autoimmune pathologies and their prognosis.
[FULL TEXT] [PDF]*
|
